Covid-19 roundup: BioN­Tech of­fers da­ta show­ing Pfiz­er-part­nered vac­cine pro­tects against vari­ant; No­vavax at­trib­ut­es ...

5 years ago
Coronavirus

Mer­ck makes good on big CV gam­ble with veri­ciguat nod — but com­pe­ti­tion will be fierce

5 years ago
FDA+

As he wraps stormy FDA tenure, Hahn ad­mits 'there was a sub­stan­tial amount of pres­sure' from White House — re­port

5 years ago
People

HHS, FDA dis­pute spills out on­to Twit­ter

5 years ago
FDA+

The IPO queue adds 5 more biotechs hop­ing to ring in 2021 by blitz­ing Nas­daq

5 years ago
Financing

News brief­ing: Beam bags a $260M pri­vate place­ment; mi­Ra­gen re­brands to Virid­i­an Ther­a­peu­tics

5 years ago
News Briefing

As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

5 years ago
Pharma
FDA+

Ox­ford gets £100M to seize a 'break­through mo­men­t' in fight­ing su­per­bugs

5 years ago
Discovery

Lon­za hits the ex­it on gel and liq­uid cap­sules, of­fload­ing 2 pro­duc­tion sites to NextPhar­ma

5 years ago
Deals
Manufacturing

Poll: Should Joshua Sharf­stein or Janet Wood­cock lead the FDA from here?

5 years ago
FDA+

Eli Lil­ly tees up dis­cov­ery pact worth more than $1.6B with Merus for T cell-fo­cused bis­pe­cif­ic an­ti­bod­ies

5 years ago
Deals
Discovery

Gilead­'s Kite re­cruits an Ab­b­Vie/NIH vet­er­an to head up cell ther­a­py R&D. And he's tak­ing aim at AML in a fe­ro­cious­ly ...

5 years ago
People

Biden el­e­vates White House sci­ence of­fice to Cab­i­net-lev­el, with ge­neti­cist Er­ic Lan­der put for­ward to lead pol­i­cy

5 years ago
People

'Bluest of blue-chip in­vestors' pump $94M in­to Sekar Kathire­san's quest to bring CRISPR to the heart

5 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: Con­va­les­cent plas­ma flops in UK tri­al; New York Gov. An­drew Cuo­mo seeks to pur­chase vac­cines ...

5 years ago
Coronavirus

An am­bi­tious GV-backed gene edit­ing up­start re-emerges as a one-drug kid­ney com­pa­ny

5 years ago
Financing
Startups

We’re poised for a new era of med­ical ad­vances. A key step: un­der­stand­ing the mol­e­c­u­lar ma­chines that gov­ern health ...

5 years ago
Biotech Voices

A car­dio­vas­cu­lar cell ther­a­py play­er grabs $54M for a new be­gin­ning — where next-gen CAR-T ap­proach fea­tures ...

5 years ago
Financing

As coro­n­avirus vari­ants trig­ger new alarms, the NIH is putting an un­der-the-radar ‘next-gen’ vac­cine in­to PhI

5 years ago
Discovery

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

5 years ago
Bioregnum
Opinion

Gilead part­ner Ar­cus earns an­a­lyst­s' plau­dits for ear­ly pan­cre­at­ic can­cer da­ta that 'ex­ceed­ed ex­pec­ta­tion­s'

5 years ago
R&D

Janet Wood­cock is in the run­ning for FDA com­mis­sion­er — what does that mean for the agen­cy's fu­ture?

5 years ago
People
FDA+

News brief­ing: Five Prime fi­nal­izes PhI­II plans for gas­tric can­cer; AI di­ag­nos­tics-fo­cused Paige ex­pands staff

5 years ago
News Briefing

Pe­ter Thiel's psy­che­delics-fo­cused ATAI ac­quires ma­jor­i­ty stake in Recog­ni­fy and its lead schiz­o­phre­nia can­di­date

5 years ago
Deals
First page Previous page 754755756757758759760 Next page Last page
A service from the Financial Times